

November 1, 2023

General Announcement:

Senju Pharmaceutical Co., Ltd.

**Launch of Distribution of the OptiLight M22 IPL Model**

Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of the OptiLight M22 IPL Model in Japan, effective immediately (medical device approval number 30400BZX00293000), where the marketing authorization holder is Lumenis BE Japan K.K. (hereinafter “Lumenis”).

The OptiLight M22 IPL Model is the newest IPL treatment device equipped with a system specialized for the ophthalmology field.

This OptiLight M22 IPL Model is indicated for improvement of symptoms of Dry Eye Disease due to MGD (Meibomian Gland Dysfunction ), and was previously approved by the Ministry of Health, Labor and Welfare in Japan.

It has a preset treatment protocol, and can provide treatment for safety and convenience by irradiating light, called IPL (Intense Pulsed Light). For more product details, please see the website of Lumenis (<https://lumenis.co.jp>).

This distribution will be implemented by way of a partnership between Senju and Lumenis. Through this alliance, Senju and Lumenis will further contribute to people’s health and prosperity by the realization and synergy of Senju’s mission of the “Pursuit of happiness for all people”, and Lumenis’ policy of “Better Technology for Better Patient Care”.

\*It is assumed to be used in combination with meibomian gland extrusion.

[Contact details for inquiries]

Medical Device Department, Senju Pharmaceutical Co., Ltd.

3-1-9, Kawara-machi, Chuo-ku, Osaka 541-0048, Japan

Mail: [medical-device@senju.co.jp](mailto:medical-device@senju.co.jp)

URL: <https://www.senju.co.jp>